Artículos de revistas
Breast Histologic Changes In Female Rats Treated With Sex Steroids [histolologia Mamária Após Uso De Esteróides Sexuais - Estudo Em Ratas]
Registro en:
Revista Da Associacao Medica Brasileira. , v. 52, n. 5, p. 369 - 374, 2006.
1044230
2-s2.0-33845730287
Autor
Vicelli J.T.
Gurgel M.S.C.
Alvarenga M.
Institución
Resumen
OBJECTIVE. To evaluate the association of histologic changes in the breasts of female rats undergoing therapy with sex steroids. METHODS. An experimental study was conducted of 40 castrated female non-pubertal rats, 20 had given birth (Group B) and 20 had no offspring (Group A). After four weeks, these rats were randomly allocated to subgroups: A1, A2, A3, A4, A5 and B1, B2, B3, B4, B5. Steroids were given to subgroups as follows: A1 and B1 - estradiol benzoate; A2 and B2 - medroxyprogesterone acetate; A3 and B3 - estradiol benzoate and medroxyprogesterone acetate; A4 and B4 - tibolone; A5 and B5 - placebo. After 10 weeks of treatment, animals were sacrificed and their mammary glands were analyzed. Histologic parameters evaluated were: epithelial cell proliferation, epithelial cells with secretory activity; and cell atypia in terminal duct units and buds or terminal alveoli. The association between microscopic analysis and diverse therapeutic regimens were analyzed by calculating the odds ratio and its respective 95% confidence interval. RESULTS. Histologic changes were observed in 29 rats: moderate hyperplasia (52.5%), hyperplastic alveolar nodule (42.5%), epithelial atypia (35%), mild hyperplasia (32.5%), secretory activity (20%) and severe hyperplasia (5%). In rats with no offspring when compared to the control, 1.3 times more hyperplastic alveolar nodules were found in the group treated with estradiol, the same was true for moderate hyperplasia in the rats that received medroxyprogesterone acetate, hyperplastic alveolar nodules and epithelial atypia in the group treated with estradiol plus medroxyprogesterone acetate. In the rats with offspring 1.3 times more secretory activity was found with estradiol. CONCLUSION. Epithelial hyperplasia and epithelial atypia with no proliferation are strongly associated to combined therapy with estradiol plus medroxyprogesterone acetate, mainly in the rats without offspring. 52 5 369 374 Maclenan, A., Lester, S., Moore, Oral oestrogen replacement therapy versus placebo for hot flushes (2002) The Cochrane Libray, (3). , (Cochrane Review). Oxford: Update Software Torgerson, D.J., Bell-Ssyer, S.E., Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials (2001) JAMA, 285, pp. 2891-2897 Oldenhave, A., Jaszmann, L.J., Haspeles, A.A., Everaerd, W.T., Impact of climateric on well-being: A survey based on 5213 women 39 to 60 years old (1993) Am J Obstet Gynecol, 168, pp. 772-780 Breast cancer and hormone replacement terapy collaborative reanalysis of data from 51 epidemiological studies 52705 women with breast cancer and 108411 women without breast cancer (1997) Lancet, 50, pp. 1047-1059. , Collaborative Group On Hormonal Factors In Breast Cancer Risk and benefits of estrogen plus progestin en healthy post menopausal women: Principal results. From the Women's Health Initiative randomized controlled trial (2002) JAMA, 288, pp. 321-323. , Writing Group for the WHI Investigators Breast cancer and hormone-replacement therapy in the Million Women Study (2003) Lancet, 362, pp. 419-427. , Million Women Study Collaborators Rymer, J.M., The effects of tibolone (1998) Gynecol Endocrinol, 12, pp. 213-220 Gompel, A., Chaouat, M., Jacob, D., Perrot, J.Y., Kloosterboer, H.J., Rostene, W., In vitro studies of tibolone in breast cells (2002) Fertil Steril, 78, pp. 351-359 Kloosterboer, H.J., Schoonen, W., Deckers, G., Effects of progestagens and org od 14 in vitro and in vivo tumor models (1994) J Steroid Biochem, 49, pp. 311-318 Stahlberg, C., Pedersen, A.T., Lynge, E., Andersen, Z.J., Keiding, N., Hundrup, Y.A., Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe (2004) Int J Cancer, 109, pp. 721-727 Hofseth, L.J., Raafat, A.M., Osuch, J.R., Pathack, D.R., Slomski, C.A., Haslam, S.Z., Hormone replacement therapy with estrogen or estrogen plus medroxiprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast (1999) J Clin Endocrinol Metab, 84, pp. 4559-4565 Russo, J., Russo, I.H., Role of hormones in cancer e initiation and progression (1998) J Mamary Gland Biol Neoplasia, 3, pp. 49-61 Clarkson, T.B., Appt, S.E., Wood, C.E., Cline, J.M., Lessons to be learned from animal studies on hormones and breast (2004) Maturitas, 49, pp. 79-89 Yang, N.N., Bryant, H.U., Hardikar, S., Sato, M., Galvin, R.J.S., Glasebrook, A.L., Estrogen and raloxifene stimulate transforming growth factor b3 gene expression in rat bone: A potential mechanism for estrogen-or roloxifene - Mediated bone maintenance (1996) Endocrinology, 137, pp. 2075-2084 Bolscher, M.T., Netelenbos, J.C., Barto, R., Buuren, L.M., Vijgh, W.J.F., Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat (1999) J Bone Min Res, 14, pp. 197-202 Ciocca, D.R., Parente, A., Russo, J., Endocrinologic milieu and susceptibility of the rat mamary gland to carcinogenesis (1982) Am J Pathol, 109, pp. 47-56 Shorr, E., A new technic for staining vaginal smears: III, a single differential stain (1941) Science, 94, pp. 545-546 Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Willians, D.C., Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hipertrophy en ovariectomized rats (1994) J Clin Invest, 93, pp. 63-69 Alvarenga, M., Cavalcanti, T.C., Tahin, Q.S., Histopathologic grading system for epitelial abnormalities induced by 7,12-dimethylbenz[a]anthracene (DMBA) in female rat mammary tissue (1989) Breast Dis, 2, pp. 71-79 Russo, J., Russo, I.H., Experimentally induced mammary tumors in rats (1996) Breast Cancer Res Treat, 39, pp. 7-20 (2003) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, pp. 64-67. , World Health Organization. Lyon: IARCPress Rosen, P.P., (2001) Rosen's Breast Pathology. 2nd Ed., , Philadelphia: Lippincott Williams & Wilkins Schnitt, S.J., The diagnosis and management of pre-invasive disease. Flat epithelial atypia: Classification, pathologic features and clinical significance (2003) Breast Cancer Res, 5, pp. 263-268 Fraser, J.L., Raza, S., Chorny, K., Connolly, J.L., Schnitt, S.J., Columnar alteration with prominent apical snouts and secretions (1998) Am J Surg Pathol, 22, pp. 1521-1527 Alvarenga, M., Tumores da mama (2004) Patologia Diagnóstica de Tumores, pp. 205-298. , Billis A, Vassallo J, editores. Campinas Shaaban, A.M., Sloane, J.P., West, C.R., Moore, F.R., Jarvis, C., Williams, E.M.I., Foster, C.R., Histopathologic types of benign breast lesions and the risk of breast cancer (2002) Am J Surg Pathol, 26, pp. 421-430 Thompson, H.J., Singh, M., Rat models of premalignant breast disease (2000) J Mammary Gland Biol Neoplasia, 5, pp. 409-420 Briand, R., Hormone dependent mammary tumors in mice and rats as a model for human breast cancer (1983) Anticancer Res, 3, p. 273 Soderqvist, G., Isaksson, E., Schoiultz, B., Carlstrom, K., Tani, E., Skoog, L., Prolifaration of breast epitelial cells in healty women during the menstrual cycle (1997) Am J Obstet Gynecol, 176, pp. 123-128 Sedgwick, C.J., Allometric scaling and emergency care: The importance of body size (1993) Zoo & Wild Animal Medicine, , Fowler ME. Philadelphia: W.B. Saunders Company Pachaly, J.R., Brito, H.F.V., Interspecific allometric scaling (2001) Biology, Medicine, and Surgery of South American Wild Animals, pp. 475-480. , Fowler ME, Cubas ZS. Iowa State University: Press/Ames Russo, J., Russo, I.H., Genotoxicit of steroidal estrogens (2004) Trends Endocrinol Metab, 5, pp. 211-214 Lieher, J.G., Genotoxicity of the steroidal oestrogens oestrone and oestradiol: Possible mechanism of uterine and mammary cancer development (2001) Hum Reprod Update, 7, pp. 273-281 Shi, Y.E., Liu, Y.E., Lippman, M.E., Dickson, R.B., Progestins and antiprogestins in mammary tumour growth and metastasis (1994) Hum Reprod, 9 (SUPPL. 1), pp. 162-173 Koukoulis, G.A., Hormone replacement therapy and breast cancer risk (2000) Ann N Y Acad Sci, 900, pp. 422-428 Simpson, H.W., Cornélissen, G., Katinas, G., Halberg, F., Meta-analysis of sequential luteal-cycle-associated changes in human breast tissue (2000) Breast Cancer Res Treat, 63, pp. 171-173 King, R.J.B., A discussion of roles of o estrogen and progestin in human mammary carcinogenesis (1991) J Steroid Biochem Mol Biol, 39, pp. 811-818 Nazário, A.C.P., Lima, G.R., Simões, M.J., Novo, N.F., Cell kinetic of the human mammary lobule during the proliferative and secretary plase of the menstrual cycle (1995) Bull Assoc Ande, 79, pp. 23-27 Bässler, R., The morphology of hormone induced structural changes in the female breast (1970) Curr Top Pathol, 53, pp. 1-89 Mustafa, I.A., Bland, K.I., Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast cancer risk (1998) Ann Surg, 228, pp. 638-651 Chen, C.L., Weiss, N.S., Newcomb, P., Barlow, W., White, E., Hormone replacement therapy in relation to breast cancer (2002) JAMA, 287, pp. 734-741 Russo, J., Russo, I.H., Differentiation and breast cancer (1997) Medicina, 57 (SUPPL. 2), pp. 81-91. , (B Aires) Grubbs, C.J., Farnell, D.R., Hill, D.L., Mc Donoug, K.C., Chemoprevention of N-nitroso-methylurea-induced mammary cancers by pretreatment with 17 b- estradiol and progesterone (1985) J Natl Cancer Inst, 74, pp. 927-931 Russo, J., Russo, I., Biological and molecular bases of mammary carcinogenesis (1987) Lab Invest, 57, pp. 112-137 Gompel, A., Kandouz, M., Siromachkova, A., The effect of tibolona on proliferation, differentiation and apoptosis in normal breast cells (1997) Gynecol Endocrinol, (SUPPL. 1), pp. 7-9 Bortoletto, C.C.R., Gonçalves, W.J., Baracat, E.C., Rodrigues De Lima, G., Giusa-Chiferi, M.G., Morphological evaluation of the endometrium of postmenopausal estrogen treatment and taking medroxiprogesterone acetate at 2,3 and 4 month (1997) Acta Obstet Gynecol Scand, 76, p. 76 Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Williams, D.C., Raloxifene (LY 139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats (1994) J Clin Invest, 93, pp. 63-69